![Melvin Spigelman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Melvin Spigelman
Direktor/Vorstandsmitglied bei
AN2 THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2026
Profil
Dr. Melvin K.
Spigelman, MD, is an Independent Director at AN2 Therapeutics, Inc., a Venture Partner at Wellington Partners GmbH and a President, Chief Executive Officer & Director at Global Alliance for TB Drug Development.
He is on the Board of Directors at AN2 Therapeutics, Inc., Global Alliance for TB Drug Development and Tres Cantos Open Lab Foundation.
Dr. Spigelman was previously employed as a Chairman by Synergy Pharmaceuticals LLC, an Independent Director by The Medicines Co., a President by Hudson-Douglas Ltd., a Vice President-Global Clinical Centers by Knoll Pharmaceuticals Ltd., a Vice President-Global Clinical Centers by Knoll Pharmaceutical Co., and an Associate Professor by Icahn School of Medicine at Mount Sinai.
He received his undergraduate degree from Brown University and a doctorate degree from Icahn School of Medicine at Mount Sinai.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Melvin Spigelman
| Unternehmen | Position | Beginn |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.02.2022 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Vorstandsvorsitzender | 01.01.2009 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Germany, Europe and beyond. The firm focuses on life sciences companies. It provides financing for early and growth stage capital requirements with an investments size of EUR 2 - 20 million. It also acts as a lead and co-lead investor. | Private Equity Investor | 01.01.2005 |
Tres Cantos Open Lab Foundation
 Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Provides research facilities for charity | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Melvin Spigelman
| Unternehmen | Position | Ende |
|---|---|---|
| SYNERGY PHARMACEUTICALS INC | Vorsitzender | 01.05.2019 |
| THE MEDICINES COMPANY | Direktor/Vorstandsmitglied | 01.01.2018 |
Hudson-Douglas Ltd. | Präsident | 01.06.2003 |
| ABBOTT INDIA LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 |
Knoll Pharmaceutical Co. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 |
Ausbildung von Melvin Spigelman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
73
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Health Technology |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Abbott India Ltd.
 Abbott India Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical, diagnostic, nutritional and hospital products | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Germany, Europe and beyond. The firm focuses on life sciences companies. It provides financing for early and growth stage capital requirements with an investments size of EUR 2 - 20 million. It also acts as a lead and co-lead investor. | Finance |
Icahn School of Medicine at Mount Sinai
 Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Knoll Pharmaceutical Co. | |
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops drugs to treat gastrointestinal disorders and diseases | Health Technology |
Hudson-Douglas Ltd. | |
Tres Cantos Open Lab Foundation
Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Provides research facilities for charity | Commercial Services |
AN2 Therapeutics, Inc.
 AN2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics | Health Technology |
